Makary pushes for IRB reforms to catch China’s speedy trial startsnews2026-03-16T18:00:27+00:00March 16th, 2026|Endpoints News|
CytomX reports ADC data in late-line colorectal cancer; FDA OKs Cosentyx label expansionnews2026-03-16T13:38:35+00:00March 16th, 2026|Endpoints News|
Nadia Care raises $12M to grow Medicaid maternal carenews2026-03-16T13:00:08+00:00March 16th, 2026|Endpoints News|
China startup CirCode gets clearance for trial of circular RNA therapynews2026-03-16T12:30:43+00:00March 16th, 2026|Endpoints News|
Structure Therapeutics reports more Phase 2 data for oral GLP-1news2026-03-16T11:32:43+00:00March 16th, 2026|Endpoints News|
After Novartis pact, macrocycle shop Unnatural Products gets $45M Series Bnews2026-03-16T11:00:17+00:00March 16th, 2026|Endpoints News|
Roche’s breast cancer failure; BioNTech co-founders to depart; Eli Lilly’s quest to stay on top; and more news2026-03-14T10:00:42+00:00March 14th, 2026|Endpoints News|
Roivant CEO, bullish on internal growth, dodges M&A chatternews2026-03-13T19:12:27+00:00March 13th, 2026|Endpoints News|
Gubra plots Roivant-like model as partnered obesity drugs take flightnews2026-03-13T15:21:57+00:00March 13th, 2026|Endpoints News|
Immutep’s LAG-3 drug fails Phase 3 lung cancer studynews2026-03-13T15:00:10+00:00March 13th, 2026|Endpoints News|
